trimethyloxamine has been researched along with Fatty Liver, Nonalcoholic in 10 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Evidence shows that trimethylamine (TMA)/trimethylamine-N-oxide (TMAO) is closely related to non-alcoholic fatty liver disease (NAFLD)." | 8.12 | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. ( Cao, P; Chen, Q; Deng, W; Gong, Z; Guo, J; Li, X; Pei, M; Shi, C; Wang, L; Wang, Y; Zhang, L, 2022) |
| "Many studies suggest that trimethylamine-N-oxide (TMAO), a gut-flora-dependent metabolite of choline, contributes to the risk of cardiovascular diseases, but little is known for non-alcoholic fatty liver disease (NAFLD)." | 7.83 | Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. ( Chen, XL; Chen, YM; Ling, WH; Liu, Y; Tan, XY; Wang, C; Wang, LJ; Zhang, HW; Zheng, RD; Zhou, RF; Zhu, HL, 2016) |
| "Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder with complicated pathophysiology." | 5.72 | Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease. ( Abdi, M; Ghaderi, D; Moloudi, MR; Moradzad, M; Rahmani, K; Sheikh Esmaeili, F; Vahabzadeh, Z, 2022) |
| "Evidence shows that trimethylamine (TMA)/trimethylamine-N-oxide (TMAO) is closely related to non-alcoholic fatty liver disease (NAFLD)." | 4.12 | Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine. ( Cao, P; Chen, Q; Deng, W; Gong, Z; Guo, J; Li, X; Pei, M; Shi, C; Wang, L; Wang, Y; Zhang, L, 2022) |
| "Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD)." | 4.02 | Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes. ( Aguilar-Salinas, C; Campos-Pérez, F; Canizales-Quinteros, S; Gómez-Pérez, F; González-González, I; Grandini-Rosales, P; Hazen, SL; Hernández-Pando, R; Huertas-Vazquez, A; Hui, ST; Larrieta-Carrasco, E; León-Mimila, P; Li, XS; López-Contreras, B; Lusis, AJ; Macías-Kauffer, L; Morán-Ramos, S; Ocampo-Medina, E; Olivares-Arevalo, M; Shih, DM; Villamil-Ramírez, H; Villarreal-Molina, T; Wang, Z, 2021) |
| "Many studies suggest that trimethylamine-N-oxide (TMAO), a gut-flora-dependent metabolite of choline, contributes to the risk of cardiovascular diseases, but little is known for non-alcoholic fatty liver disease (NAFLD)." | 3.83 | Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. ( Chen, XL; Chen, YM; Ling, WH; Liu, Y; Tan, XY; Wang, C; Wang, LJ; Zhang, HW; Zheng, RD; Zhou, RF; Zhu, HL, 2016) |
| "Choline is a water-soluble nutrient essential for human life." | 2.66 | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. ( Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020) |
| "Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide but still lacks specific treatment modalities." | 1.91 | Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro. ( Jin, N; Lu, X; Nian, F; Wu, L; Xia, Q; Zhu, C, 2023) |
| "Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder with complicated pathophysiology." | 1.72 | Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease. ( Abdi, M; Ghaderi, D; Moloudi, MR; Moradzad, M; Rahmani, K; Sheikh Esmaeili, F; Vahabzadeh, Z, 2022) |
| "Liver fibrosis is one main histological characteristic of nonalcoholic steatohepatitis (NASH), a disease paralleling a worldwide surge in metabolic syndromes with no approved therapies." | 1.72 | Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis. ( Ding, BS; Mo, C; Xiao, C; Zhang, J; Zhou, D, 2022) |
| "However, its role in nonalcoholic steatohepatitis (NASH) is unknown." | 1.51 | Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats. ( Fan, JG; Liu, XL; Pan, Q; Xin, FZ; Xue, YQ; Yang, RX; Zhao, ZH; Zhou, D, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, C | 1 |
| Pei, M | 1 |
| Wang, Y | 1 |
| Chen, Q | 1 |
| Cao, P | 1 |
| Zhang, L | 1 |
| Guo, J | 1 |
| Deng, W | 1 |
| Wang, L | 2 |
| Li, X | 1 |
| Gong, Z | 1 |
| Moradzad, M | 1 |
| Abdi, M | 1 |
| Sheikh Esmaeili, F | 1 |
| Ghaderi, D | 1 |
| Rahmani, K | 1 |
| Moloudi, MR | 1 |
| Vahabzadeh, Z | 1 |
| Zhou, D | 2 |
| Zhang, J | 1 |
| Xiao, C | 1 |
| Mo, C | 1 |
| Ding, BS | 1 |
| Nian, F | 1 |
| Zhu, C | 1 |
| Jin, N | 1 |
| Xia, Q | 1 |
| Wu, L | 1 |
| Lu, X | 1 |
| Arias, N | 1 |
| Arboleya, S | 1 |
| Allison, J | 1 |
| Kaliszewska, A | 1 |
| Higarza, SG | 1 |
| Gueimonde, M | 1 |
| Arias, JL | 1 |
| León-Mimila, P | 1 |
| Villamil-Ramírez, H | 1 |
| Li, XS | 1 |
| Shih, DM | 1 |
| Hui, ST | 1 |
| Ocampo-Medina, E | 1 |
| López-Contreras, B | 1 |
| Morán-Ramos, S | 1 |
| Olivares-Arevalo, M | 1 |
| Grandini-Rosales, P | 1 |
| Macías-Kauffer, L | 1 |
| González-González, I | 1 |
| Hernández-Pando, R | 1 |
| Gómez-Pérez, F | 1 |
| Campos-Pérez, F | 1 |
| Aguilar-Salinas, C | 1 |
| Larrieta-Carrasco, E | 1 |
| Villarreal-Molina, T | 1 |
| Wang, Z | 1 |
| Lusis, AJ | 1 |
| Hazen, SL | 1 |
| Huertas-Vazquez, A | 1 |
| Canizales-Quinteros, S | 1 |
| Flores-Guerrero, JL | 1 |
| Post, A | 1 |
| van Dijk, PR | 1 |
| Connelly, MA | 1 |
| Garcia, E | 1 |
| Navis, G | 1 |
| Bakker, SJL | 1 |
| Dullaart, RPF | 1 |
| Tan, X | 1 |
| Liu, Y | 2 |
| Long, J | 1 |
| Chen, S | 1 |
| Liao, G | 1 |
| Wu, S | 1 |
| Li, C | 1 |
| Ling, W | 1 |
| Zhu, H | 1 |
| Zhao, ZH | 1 |
| Xin, FZ | 1 |
| Xue, YQ | 1 |
| Liu, XL | 1 |
| Yang, RX | 1 |
| Pan, Q | 1 |
| Fan, JG | 1 |
| Chen, YM | 1 |
| Zhou, RF | 1 |
| Chen, XL | 1 |
| Wang, C | 1 |
| Tan, XY | 1 |
| Wang, LJ | 1 |
| Zheng, RD | 1 |
| Zhang, HW | 1 |
| Ling, WH | 1 |
| Zhu, HL | 1 |
1 review available for trimethyloxamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Topics: Animals; Biological Availability; Cardiovascular Diseases; Choline; Diet; Dysbiosis; Gastrointestina | 2020 |
9 other studies available for trimethyloxamine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine.
Topics: Animals; Cell Line; Endoplasmic Reticulum Chaperone BiP; Gastrointestinal Microbiome; Gene Silencing | 2022 |
Possible correlation between high circulatory levels of trimethylamine-N-oxide and 2177G>C polymorphisms of hepatic flavin containing monooxygenase 3 in Kurdish Population with non-alcoholic fatty liver disease.
Topics: Case-Control Studies; Chromatography, Liquid; Flavins; Humans; Methylamines; Mixed Function Oxygenas | 2022 |
Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis.
Topics: Animals; Disease Models, Animal; Gastrointestinal Microbiome; Liver Cirrhosis; Methylamines; Mice; N | 2022 |
Gut microbiota metabolite TMAO promoted lipid deposition and fibrosis process via KRT17 in fatty liver cells in vitro.
Topics: Fibrosis; Gastrointestinal Microbiome; Humans; Lipids; Liver Cirrhosis; Methylamines; Non-alcoholic | 2023 |
Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.
Topics: Adult; Betaine; Bile Acids and Salts; Biomarkers; Biopsy; Choline; Diabetes Mellitus, Type 2; Female | 2021 |
Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease.
Topics: Biomarkers; Cohort Studies; Humans; Methylamines; Non-alcoholic Fatty Liver Disease; Oxides; Prospec | 2021 |
Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease.
Topics: Adult; Animals; Bile Acids and Salts; Case-Control Studies; Cholesterol 7-alpha-Hydroxylase; Diet, H | 2019 |
Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats.
Topics: Administration, Oral; Animals; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Disease | 2019 |
Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults.
Topics: Adolescent; Adult; Aged; Betaine; Biomarkers; Case-Control Studies; Choline; Chromatography, High Pr | 2016 |